Online health and wellness company Hims & Hers is evolving its direct-to-consumer telehealth and prescription drug platform, with plans to add blood-sample collection diagnostics.
The company also entered the Canadian market to launch its weight loss program there, coinciding with the anticipated availability of generic semaglutide. In July, the company signaled it was preparing to expand its digital weight-loss program to Canada by selling a generic version of semaglutide, the ingredient in Novo Nordisk's branded blockbusters Ozempic and Wegovy.
Hims & Hers' entry into Canada follows the recent completion of its acquisition of Livewell, a Canadian digital health platform offering access to a variety of treatments, with a focus on weight loss. That deal follows a string of acquisitions this year. The company bought Zava, a digital health platform in Europe, to launch its business in Germany, France and Ireland. The acquisition will also expand Hims & Hers’ presence in the UK. It also acquired a U.S.-based peptide facility based in California to expand its production of peptide treatments.
Hims & Hers announced this week that it agreed to acquire YourBio Health, Inc., a Boston-based pioneer in capillary whole blood sampling technology. The acquisition will help accelerate efforts to "redefine and modernize the overall blood collection experience, making pain-free blood sampling the new standard," the company said in a press release.
Financial terms of the deal were not disclosed. The deal is expected to close in early 2026, subject to customary regulatory approvals and closing conditions. Consideration is comprised entirely of cash funded from Hims & Hers’ balance sheet, the company said.
The deal will enable Hims & Hers to add YourBio Health's "Touch-Activated Phlebotomy" (TAP) device to its offerings. YourBio Health's TAP devices use bladeless microneedles thinner than an eyelash to produce high-quality capillary blood samples in seconds, without the pain or complexity of traditional methods, like fingerstick or venipuncture, according to the company.
The diagnostic company's technologies are designed to simplify the process and expand when, where, and how blood samples can be collected, Hims & Hers said.
The acquisition will fuel Hims & Hers' "in-house innovation engine and redefining what’s possible in user-centric blood sampling,' executives said in a press release.
Michael Mina, M.D., Chief Scientific Officer at YourBio Health and Paul Owen, CEO of the company, will join the Hims & Hers team.
"The next generation of health innovation will be built on proprietary technologies that make wellness simpler, more comfortable, and more human,” said Andrew Dudum, founder and CEO of Hims & Hers, in a statement. “YourBio’s patented TAP and HALO technologies represent major advancements in user experience and design, and we’re excited to bring them into the Hims & Hers ecosystem.”
Mina said YourBio Health's technology has the potential to "change how people engage with routine blood collection – replacing long waits and painful needles with a far more convenient, user-friendly experience.”
The acquisition follows Hims & Hers' recent move into lab testing. Last month, the company announced a new Labs offering that enables customers to get a blood test at a local Quest Diagnostics lab and have the results analyzed. The Labs plans to test for 50 biomarkers, and up to 120 biomarkers, depending on the plan. Hims & Hers will then provide customers with personalized treatment plans.
The lab business will include areas like heart health, metabolism, hormones, inflammation and stress.
A base plan includes a yearly blood draw that captures 50 biomarker tests across 9 categories and is available for $199 a year. An advanced plan includes two yearly blood draws that capture over 120 biomarker tests across 10 key categories and is available for $499 a year.
Dudum told the Wall Street Journal he expects the offering to eventually represent a $1 billion business.
Hims & Hers also contributed to a $325 million private placement in Grail, which develops blood tests to detect cancer.
The company is looking to boost growth beyond its weight-loss and sexual health offerings with a focus on preventive care. These moves also come as the GLP-1 market rapidly shifts. Last month, President Donald Trump announced deals with Eli Lilly and Novo Nordisk to reduce the prices of GLP-1 drugs.